Order results by:
| Issue | Title | |
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... -to-pay threshold (WTP), the threshold value of the incremental cost-effectiveness ratio (ICeR), in europe ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... . The incremental cost-effectiveness ratio (ICER) for QALY in the baseline scenario was 3,598,156 rubles, the ICER ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... cost-effectiveness standard, it was 1,748,623.36 Rub for QALY; according to the method ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... and effectiveness in terms of QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combination ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... of life years gained (LYG) and quality-adjusted life years (QALY) were calculated. Results were compared ..." | ||
| Vol 9, No 3 (2016) | METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... antibiotic in the therapy of acute obstructive bronchitis,. The highest value ICER ratio was obtained ..." | ||
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva | ||
| "... This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... healthcare system point of view. Incremental cost-effectiveness ratio (ICER) for BV vs Ch ± RT and Ch ± RT ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... gained (LYGs) and 1.12 quality-adjusted life years (QALYs) per 1 patient during lifelong therapy ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... group compared to the DT group. Incremental cost-effectiveness ratio (ICER) per 1 QALY constituted 2 ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... -adjusted life years - QALY. The analysis will be performed for the health systems. Mean QALY in the first ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..." | ||
| Vol 17, No 3 (2024) | Review of open libraries for pharmacoeconomic analysis in R environment | Abstract similar documents |
| I. A. Lackman, R. I. Sladkov, V. M. Timiryanova | ||
| "... interventions (DALY, QALY, ICER), libraries for performing sensitivity analysis of the effect of medical ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... эффективности, в качестве критериев эффективности были использованы значения добавленных лет жизни (LYG) и ..." | ||
| Vol 6, No 3 (2013) | METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES | Abstract similar documents |
| R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze | ||
| Vol 12, No 3 (2019) | Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract similar documents |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| "... -adjusted life year (incremental cost-effectiveness ratio (ICER) per QALY). The result for ticagrelor ..." | ||
| Vol 16, No 4 (2023) | Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma | Abstract similar documents |
| S. K. Zyryanov, K. V. Orlova | ||
| "... of life years gained (LYGs) depending on the treatment regimen were calculated using approximated overall ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... direct healthcare costs and incremental cost-effectiveness ratios (ICERs) per 1 life year gained were ..." | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION | Abstract similar documents |
| V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina | ||
| "... (QALY) is growing, which makes it advisable to use ART in health care on larger scale. ..." | ||
| Vol 14, No 2 (2021) | Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation | Abstract similar documents |
| D. G. Shchurov, V. S. Dombrovskiy | ||
| "... ; incremental cost-effectiveness ratio (ICER); changes in the amount of total direct medical costs; resizing ..." | ||
| Vol 7, No 3 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA | Abstract similar documents |
| A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova | ||
| "... .1%. ICER for eloxatin was 8,801 and 18,162 compared to eksorum and platikad respectively. As a result ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| "... , improves the quality of life of patients, adding 0.73 QALY per patient. Modelling suggests ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... ) with a recalculation into quality-adjusted life-year (QALY). The time horizon of the cost-effectiveness analysis was 2 ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year ..." | ||
| Vol 8, No 2 (2015) | ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA | Abstract similar documents |
| Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov | ||
| "... as it had clinical benefits with affordable additional expenses. The increment cost efficiency rate (ICER ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... -effectiveness ratios (ICER) were 24,530.20 and 21,526.50 rubles per 1 patient. Markov model was developed ..." | ||
| Vol 11, No 3 (2018) | Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review | Abstract similar documents |
| D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin | ||
| "... (QALYs), adverse events, and other clinical outcomes. The search for the relevant information ..." | ||
| Vol 14, No 4 (2021) | Economic burden of chronic viral hepatitis C | Abstract similar documents |
| R. A. Yakhina, I. A. Lakman, D. A. Valishin, R. Kh. Bakhitova | ||
| "... , quality of life adjustment tools (QALY or DALY) were used to estimate the global economic burden. A third ..." | ||
| Vol 10, No 4 (2017) | PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... on the ICER analysis, the additional expenses associated with a wider use of preventive therapy in scenarios 1 ..." | ||
| Vol 15, No 3 (2022) | Economic burden of the novel coronavirus infection: a systematic review | Abstract similar documents |
| V. M. Timiryanova, I. A. Lakman, N. Sh. Zagidullin, D. F. Gareeva | ||
| "... of quality-adjusted life years lost (QALY) (66.3%), 37.6% of the studies are based on the results ..." | ||
| 1 - 32 of 32 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
